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Stroke- the most important cause of the newly
diagnosed epilepsy in the elderly
Abstract
About 35% of all newly diagnosed epileptic seizures in people older than
60 years are caused by stroke. The incidence of the early epileptic seizures is
2.4–5.4%, and for the late seizures 3–4.5%. Seizures after stroke are most
often simple partial seizures with or without secondary generalization, and
less often complex partial seizures. In early seizure these are acute biochemical
cellular changes, and in late seizures gliosis. Althoung the risk for developing
epilepsy was 17–35% after early seizures, the risk of developing epilepsy after
late seizures increased to 65–90%. Combination of coronary heart disease,
hypertonia and cardiovascular disease occur in 65% of patients over 75 year
old. Intrahospital mortality in patients with stroke with epileptic seizures was
37.9% compared to patients without seizures (14.4%). Early seizures cause
higher mortality than late seizures which can be explained by sinergistic effect
of of the damaged tissue due to the seizure and vascular ischaemia. European
authors in 2007 indicate that lavetiracetam, lamotrigine and gabapentin
were first line drugs, followed by topiramate and valproate in elderly patients.
Oxcarbazepine and carbamazepine were not highly recommended because of
the associated hyponatremia, cardiac disorders and interaction potentials. The
standard antiepileptic drug for focal epilepsy is still carbamazepine, and
valproate is most commonly used for generalized epilepsy- even in older
patients. Epidemiological studies on epilepsy treatment in the elderly show
steady increase in the number of patients. Therefore, elderly patients require
special attention. Monotherapy in low doses is often sufficient, enzyme induc-
ing drug are used too frequently.
INTRODUCTION
Epilepsy and epileptic seizures are one of the most common andmost serious neurological conditions worldwide. Epilepsy cur-
rently affects 1–1.5% of elderly population, and its prevalence and
incidence rise as the number of old people increases worldwide.
Currently, epileptic seizures are the third most common neuro-
logical disorder in the elderly. Only cerebrovascular disorders and de-
mentias are more prevalent (1). Ramsay et al. (2) investigated the
distribution of different seizure types among the elderly and found that
focal seizures (simple partial and complex partial with or without
secondary generalization) occured most frequently (73%). Tonic clonic
status epilepticus was more frequent in older patients than in younger
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epilepsy cases among the elderly (3), whereas non-con-
vulsive SE was found most frequently in adults near 60
years of age (4).
STROKE AND EPILEPSY
About 35% of all newly diagnosed epileptic seizures in
people older than 60 years are caused by stroke. Their
coexsistence worsens medical and social prognosis and
worsens invalidity.
Until now it has been well established that epileptic
seizures can be provoked not only as a result of stroke,
but also as a presenting symptom of stroke as well as the
risk factor for the future subclinical cerebrovascular dise-
ase (5).
There are diferent studies in the literature identifying
incidence of epilepsy after stroke and taking all of them
into account the incidence would be 3–15%.
The most important clinical studies connected to this
topic comes from population based registers. One of the
first performed is Rotterdam study, pointing that patients
with stroke have increased risk to develop epilepsy (6).
Hauser et al. have demonstrated that cerebrovascular
disease count for 11% of epilepsy causes (7). Forsgren et
al show that in patients older than 60, etiology of epilepsy
is known in 77% of the patients, with stroke being the
cause of epilepsy in 45% of the patients (8). So et al has
determined that the most probable period to develop
epilepsy is one year after stroke. Comparing people with
stroke with age and sex matched controls there is a 17
times higher risk to develop epilepsy in stroke group (9).
At our department for Neurology we have retrospec-
tivelly analyzed 1449 patients with epilepsy who were
admitted during the year 2003 and 2004. 21.5% of the
patients were older than 65 years. The etiology of the
seizures was: cerebrovascular disease in 54.1%, alcoho-
lism in 13.5%, trauma in 8.5%, primary tumors in 4.98%,
metastatic tumors in 4.6% and meningoencephalitis in
1.4% of the patients (10) (Figure 1).
Concerning risk factors for first seizure after stroke,
one study created a multivariate analysis model for re-
mote, symptomatic seizures that included cortical in-
volvement, lesion size and prior lesions. The risk for
acute seizures included cortical involvement, alcohol con-
sumption and hamorrhagic stroke and prior lesion on a
CT scan (11). In the present sudies cortical involvement
is an independent risk factor (12), in other studies, epi-
leptic seizures are connected to the size of ischaemic le-
sion (13). Lisette et al have shown that the risk to develop
early epileptic seizures increase up to 8 times in patients
with cardioembolic stroke in the temporal gyrus or poste-
rior central gyrus, and 5 times in patients with supra-
marginal gyrus or superior temporal gyrus (14). Epilepsy
is less common in cerebellar stroke of the deep cerebral
structures, although there are some described seizures in
those locations as well. Seizures are described also in
lacunar infarcts in 1–3% (15).
Epileptic seizures can trigger stroke meaning that epi-
leptic seizures have to be taken seroiously as a risk for deve-
loping stroke. The relative risk for developing stroke is 2.89
in patients with late onset seizure, the risk which could
be compared to 1.4 risk with low HDL cholesterole (16).
Epileptic seizures can be the first symptome of stroke.
Giroud et al. 1994 (17) has analyzed 90 patients with
early epileptic seizures after stroke where 89% patients
had seizures as the first symptome of stroke. In other
studies early seizures after stroke have developed in 40–78%
of the patients within 24 hours.
Seizures after stroke are most often simple partial
seizures with or without secondary generalization, and
less often complex partial seizures. In two out of nine
studies it has been shown that generalized tonic clonic
seizures develop more often after stroke. Haemorrhagic
transformation in ischaemic stroke increases risk for de-
veloping seizures. Seizures that developed at the be-
ginning of stroke were more often present in haemorrha-
gic infarct (19.2%) than cerebral haemorrhagia (15.6%)
or ischaemic infarct (6.2%) (18).
EARLY AND LATE SEIZURES
Symptomatic epilepsy can be best described as ethio-
logical reaction of the brain on the damage of all kinds. In
patients with stroke there are two different types of epi-
leptic seizures: early and late epileptic seizures.
As in posttraumatic epilepsy, there are different patho-
physiological processes connected to early and late sei-
zure onset after stroke. In early seizure these are acute
biochemical cellular changes, and in late seizures gliosis.
Early seizures can develop after homeostatic and sys-
temic disturbances as electrolite disbalanse and acido-
base balance. Early seizures are categorized as „acute
symptomatic epileptic sizures“ and should be distin-
guished from genuine epilepsy.
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Figure 1. Etiology of epileptic seizures in 312 patients older than 65 years who
were hospitalized during 2003–2004 at the University Department for Neuro-
logy, University Hospital Center „Sestre milosrdnice“, Zagreb, Croatia.
In the present literature we can find different defi-
nitions for these conditions, but until now there has been
an agreement that early seizures develop within 14 days
from the stroke onset, and late seizures after 14th day.
The given distribution is important due to different patho-
physiological mechanisms that cause these conditions.
The most important practical value of this allocation in
two cathegories is the different prognosis, because the
most patients with early seizures do not develop late
seizures and epilepsy.
Based on the results derived from animal studies, in
early seizures (after 2 weeks of ischaemia), patients dis-
played increased levels of penumbral sodium, intracellu-
lar calcium and excitatory glutamate as well as down-re-
gulation of GABAergic inhibition (19, 20). Damaged
tissue contains: increased release of excitotoxic glutamate
and impairment of the GABA neurons. Epileptic seizu-
res can lead to secondary excitotoxic glutamate damage
leading to higher energetic demand in the conditions of
ischaemia causing possible irreversible tissue damage. In
cases of late seizures, one study reported the disinhi-
bition or development of excitatory axon sprouting and
the presence of hemosiderin, gliosis and altered mem-
brane function (21).
Neuronal changes develop in late seizures, the patho-
genesis of which is until now not fully understood. The
possible reasons for epileptogenesis are: selective neu-
ronal death and apoptosis, membrane changes, mito-
chondrial changes, receptore changes (for example GABA
receptors), deafferentiation and collateral sprouting (at
ischaemia site as well as distant places) (22). Penumbra is
also considered to contain electrical irritable tissue re-
sembling epileptogenic focus (23).
Experimental studies show that repeated epileptoge-
nic activity in cerebral ischaemia significantly increases
the size of the infarct zone and can cause functional
worsening of the patient (24).
The incidence of the early epileptic seizures is 2.4–5.4%,
and for the late seizures 3–4.5%. In 3.7% epileptic sei-
zures are connected to transitive ischaemic attack (25). It is
possible that some epileptic attacks are in fact myoclonisms
of the extremities within transitive ischaemic attack (TIA)
due to the ischaemia in the border zone and do not
actually represent epileptic seizures. Between 2.3 and
10.5% of the patients experience single seizure following
stroke (21, 26). At 1 year after stroke, the cumulative risk
of seizures is 4.2%, mounting to 9.7% after 5 years (27).
Transient ischaemic attacks rarely cause epileptic sei-
zures (27).
Althoung the risk for developing epilepsy was 17–35%
after early seizures (1 week after stroke), the risk of
developing epilepsy after late seizures increased to 65–90%
(29, 30).
Patients exhibiting frontal intermittent rhytmic delta
activity and diffuse slowing on post-stroke EEGs have a
high risk of developing late onset seizures (31).
COMORBIDITY
The comorbidities in elderly patients with epilepsy
and stroke include: psychiatric problems (e.g. depres-
sion), sleep disorders (e.g. insomnia), cardiovascular dis-
turbances, cardiac arrhytmias, AV block and hypotonia,
osteoporosis, gait disturbances and tremor.
Combination of coronary heart disease, hypertonia
and cardiovascular disease occur in 65% of patients over
75 year old (25, 32).
MORTALITY
The standardized mortality rate in patients with epi-
lepsy is double that observed in the healthy population
(33). Intrahospital mortality in patients with stroke with
epileptic seizures was 37.9% compared to patients with-
out seizures (14.4%). In the first 30 days following acute
symptomatic epilepsy, the fatality rate in elderly patients
was double that of younger patients (34). It is not known
to what size the epileptic sezures themselves represent
prognostic factor for the outcome or whether they are
only indicator of the severity of stroke. Early seizures
cause higher mortality than late seizures which can be
explained by sinergistic effect of of the damaged tissue
due to the seizure and vascular ischaemia.
TREATMENT
Acute epileptic seizures in stroke are managed in
Intensive care unit in case of epileptic status. Cases of
isolated epileptic seizures do not demand antiepileptic
therapy.
Retrospective studies have shown that early epileptic
seizures do not require longterm antiepileptic therapy
for the prevention of subsequent seizure, whereas late
seizures require specific antiepileptic treatment (31). Some
centers apply AET during 3–6 months after stroke, alt-
hough the exact period is not determined in the present
studies.
It has to be taken into account that the choice of AED
depends on: age, severity of stroke, comorbidity and other
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Figure 2. Initial antiepileptic therapy in patients with stroke and epilepsy at
the Univeristy Department of Neurology, University Hospital Center „Sestre
milosrdnice“ hospitalized from 2003–2004. (MPB-methylphenobarbiton,
CBZ-carbamazepine, VPA-valproate).
drugs taken by patients. Physiological changes in the
absorption, distribution, biotransformation, excretion and
interaction with other drugs occur with aging. Aging
causes changes in the function of several organs that can
affect treatment. Reduced liver metabolism and decreas-
ed clearance can lead to increased concentrations of AED
to even toxic doses (25). Liver volume and mass in elderly
patients is up to 20% lower with of the liver metabolism
of the AED which are metabolized through citochrome
oxidase, especially seen in carbamazepine, phenytoin,
phenobarbitone and valproic acid. As opposed to liver
metabolism, decresed kidney clearance is mitigated con-
stantly and predictably. In elderly patients, adverse drug
reactions are one of the major limiting factor in patient
retention (35). Toxic effect of the AED is manifested as:
sedation and behavioral changes (clonazepam, pheno-
barbitone, primidone), tremor (valproic acid) and hypo-
natremia (carbamazepine). Although adverse effects have
been reported during lamotrigine therapy, these effects
occured more often during treatment with phenitoyn
and carbamazepine. Of the 10 studies dealin with ef-
ficacy and safety of newer antiepileptic drugs since 2000,
only one study proved Class 1 evidence (35, 36).
At our department for Neurology we have retrospec-
tivelly analyzed 1449 patients with epilepsy who were
admitted during the year 2003 and 2004. 21.5% of the
patients were older than 65 years. Newly diagnosed
epilepsy was present in 19,4% of the patients.
Initial antiepileptic treatment was carried out with:
methylphenobarbital in 86 patients (30,6%), carbama-
zepine in 97 patients (34,5%), carbamazepine and meth-
ylphenobarbiton in 9 patients (3,2%), valproate in 8 pa-
tients (2,8%), diazepam in 11 patients (3,9%) and
oxazepam in 7 patients (2,5%). Later during follow-up
lamotrigin was introduced as monotherapy in 9 patients
(3,2%) and in 9 patients as add-on therapy. Topiramate
was introduced in 7 patients as monotherapy (2,5%), in 4
patients (1,4%) as add-on therapy. Gabapentin was in-
troduced in 4 patients (1,4%) as monotherapy and in 2
patients (0,7%) as add-on therapy (Fig.2).
US expert rating indicated that the first line drugs to
treat epilepsy in the elderly are: lamotrigine, levetira-
cetam, gabapentin, carbamazepine and oxcarbamazepi-
ne, which are followed by topiramate and valproate (37).
European authors in 2007 indicate that lavetiracetam,
lamotrigine and gabapentin were first line drugs, fol-
lowed by topiramate and valproate. Oxcarbazepine and
carbamazepine were not highly recommended because
of the associated hyponatremia, cardiac disorders and
interaction potentials (38).
The potential for drug interaction is extremely im-
portant because elderly patients are commonly treated
with multiple medications. Carbamazepine, phenytoin,
phenobarbital and primidone are strong enzyme indu-
cers, whereas valproate is an enzyme inhibitor. Some
AED can slow down recovery from stroke, for example
phenitoin in combination with GABA agents (39).
Carbamazepine may influence arterio-ventricular
conduction and should not be used in AV block; it can
also increase osteoporosis and has considerable inter-
action potential with warfarin. Valproate can be admi-
nistered once daily and it has a broad efficacy spectrum
against focal and generalized epilepsy. Particular atten-
tion must be paid to certain side effects in elderly patients
as: encephalopathy, tremor and interactions with anti-
coagulats. Valproate may increase insidious dementia
and Parkinsonian syndrome (40). Gabapentin, prega-
balin, levetiracetam, lamotrigine and topiramate do not
have any interactions with anticoagulats, however gab-
apentin, pregabalin and levetiracetam can alter kidney
function. Levetiracetam can cause emotional disturban-
ce and topiramate may produce cognitive side effects-
especially when used as add on therapy at higher dos-
ages. In monotherapy, topiramate at doses up to 100mg is
generally well tolerated. Tremor and insomnia are
possible side effects of lamotrigine.
Osteoporosis is common in elderly women and occurs
in 15–40% of patients with enzyme-inducing anticon-
vulsants (41). Carbamazepine, phenobarbitone, pheny-
toin, primidone and valproate have marked effects on
osteoporosis. There is not enough evidence for gaba-
pentin, pregabalin and levetiracetam on osteoporosis,
however levetiracetam may reduce bone strenght and
bone formation without altering bone mass. Lamotrigine
monotherapy was not associated with decreased bone
density. During treatment with phenobarbital, pheny-
toin and carbamazepine, gate disturbances were found
in 42–55% of the patients older than 65 years (18).
Although lamotrigine, levetiracetam and topiramate
have been used with increasing frequency, phenytoin
was still the most commonly used AED. In the last
decade, there has been a small reduction in the use of
phenytoin (from 70 to 66%) and phenobarbital (from 3 to
1%). This reduction is correlated with the increased use
of newer antiepileptic drugs (from 12.9 to 19.8%) (39).
The standard antiepileptic drug for focal epilepsy is
still carbamazepine, and valproate is most commonly
used for generalized epilepsy- even in older patients.
Epidemiological studies on epilepsy treatment in the
elderly show steady increase in the number of patients.
Therefore, elderly patients require special attention. Mo-
notherapy in low doses is often sufficient, enzyme in-
ducing drug are used too frequently (42, 43).
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